Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
ALLOPURINOL
NU-PHARM INC
M04AA01
ALLOPURINOL
300MG
TABLET
ALLOPURINOL 300MG
ORAL
100/500
Prescription
ANTIGOUT AGENTS
Active ingredient group (AIG) number: 0103654003; AHFS:
CANCELLED (UNRETURNED ANNUAL)
2018-03-28
0 PRODUCT MONOGRAPH NU-ALLOPURINOL ALLOPURINOL TABLETS USP 100, 200 AND 300 MG XANTHINE OXIDASE INHIBITOR NU-PHARM INC. DATE OF PREPARATION: 50 MURAL STREET, UNITS 1 & 2 OCTOBER 7, 2009 RICHMOND HILL, ONTARIO L4B 1E4 CONTROL#: 133281 1 PRODUCT MONOGRAPH NU-ALLOPURINOL Allopurinol Tablets USP 100, 200 and 300 mg THERAPEUTIC CLASSIFICATION Xanthine Oxidase Inhibitor ACTIONS AND CLINICAL PHARMACOLOGY Allopurinol is a structural analogue of hypoxanthine. Reduction in both the serum and urinary uric acid levels is brought about by allopurinol inhibiting the action of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol, which is also an inhibitor of xanthine oxidase. The action of allopurinol in blocking formation of urate differs from that of uricosuric agents which lower the serum uric acid level by increasing urinary excretion of uric acid. INDICATIONS AND CLINICAL USE Treatment of gout, either primary, or secondary to hyperuricemia which occurs in blood dyscrasias and their therapy. Treatment of primary or secondary uric acid nephropathy, with or without accompanying signs or symptoms of gout. Prophylactically, to prevent tissue urate deposition or renal calculi in patients with leukemias, lymphomas or other malignancies, receiving antineoplastic treatment (radiation or cytotoxic drugs) which might induce increased uricemia levels. Also in the therapy and prophylaxis of 2 acute urate nephropathy and resultant renal failure in patients with neoplastic disease who are particularly susceptible to hyperuricemia and uric acid stone formation (especially after radiation therapy or use of antineoplastic drugs). Prevention of the occurrence and recurrence of uric acid stones or gravel and renal calcium lithiasis in patients with hyperuricemia and/or hyperuricosuria. CONTRAINDICATIONS Should not be given to patients who are hypersensitive to allopurinol or who have previously developed Izlasiet visu dokumentu